FIN-524, a microbial cocktail for the treatment of ulcerative colitis, is our first product candidate based on a rationally designed, synthetic ecology of microbes. FIN-524 leverages Finch’s human-first discovery platform, using a diversity of clinical datasets to identify the specific strains responsible for driving the promising efficacy observed with fecal microbiota transplantation in ulcerative colitis.

Finch and Takeda are collaborating to jointly develop FIN-524. The collaboration combines Finch’s unique discovery platform with Takeda’s strength in drug development for gastrointestinal diseases to advance this new class of microbial therapy